Today, Precigen, Inc., the parent company of Trans Ova Genetics, L.C. (“Trans Ova”), announced a definitive agreement for the sale of Trans Ova to URUS. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Trans Ova is an industry-leading provider of bovine reproductive technologies. Trans Ova’s dedication and strong commitment to its clients, which has sustained its outstanding reputation in the industry, will continue unabated. Trans Ova will continue under the leadership of David Faber, D.V.M, CEO & President, and his current management team.
URUS is dedicated to serving beef and dairy producers through a family of businesses that provide cutting edge products, genetics, and herd management information.
View press release
“Trans Ova will continue to Multiply Success for current and future clients with the same exceptional team, same convenient locations, and the same toolbox of services, while maintaining the standard of excellence that clients have come to expect throughout our 40 years of experience in reproductive technologies.
We look forward to continuing to serve our existing clients and, upon closing of the transaction, working with URUS to add strategic resources to our company that further enhance our ability to provide leading assisted reproductive technologies.”
David Faber, D.V.M
CEO & President
Trans Ova Genetics
